- Home
- FTHY vs ATAI Comparison
FTHY vs ATAI Comparison
Compare FTHY & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTHY
- ATAI
- Stock Information
- Founded
- FTHY 2020
- ATAI 2018
- Country
- FTHY United States
- ATAI Germany
- Employees
- FTHY N/A
- ATAI N/A
- Industry
- FTHY Investment Managers
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- FTHY Finance
- ATAI Health Care
- Exchange
- FTHY Nasdaq
- ATAI Nasdaq
- Market Cap
- FTHY 500.1M
- ATAI 444.7M
- IPO Year
- FTHY N/A
- ATAI 2021
- Fundamental
- Price
- FTHY $14.46
- ATAI $2.48
- Analyst Decision
- FTHY
- ATAI Strong Buy
- Analyst Count
- FTHY 0
- ATAI 3
- Target Price
- FTHY N/A
- ATAI $10.50
- AVG Volume (30 Days)
- FTHY 176.7K
- ATAI 2.7M
- Earning Date
- FTHY 01-01-0001
- ATAI 08-12-2025
- Dividend Yield
- FTHY 10.93%
- ATAI N/A
- EPS Growth
- FTHY N/A
- ATAI N/A
- EPS
- FTHY N/A
- ATAI N/A
- Revenue
- FTHY N/A
- ATAI $1,863,000.00
- Revenue This Year
- FTHY N/A
- ATAI $554.22
- Revenue Next Year
- FTHY N/A
- ATAI N/A
- P/E Ratio
- FTHY N/A
- ATAI N/A
- Revenue Growth
- FTHY N/A
- ATAI 572.56
- 52 Week Low
- FTHY $12.66
- ATAI $1.03
- 52 Week High
- FTHY $14.74
- ATAI $2.64
- Technical
- Relative Strength Index (RSI)
- FTHY 59.61
- ATAI 66.50
- Support Level
- FTHY $14.37
- ATAI $2.06
- Resistance Level
- FTHY $14.48
- ATAI $2.55
- Average True Range (ATR)
- FTHY 0.09
- ATAI 0.20
- MACD
- FTHY -0.00
- ATAI -0.02
- Stochastic Oscillator
- FTHY 72.38
- ATAI 72.41
About FTHY First Trust High Yield Opportunities 2027 Term Fund
FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND is a diversified, closed-end management investment company. The investment objective of the fund is to provide current income.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.